Target for cancer therapy: proliferating cells or stem cells (Q36343524)

13 August 2017

1 reference

title

Target for cancer therapy: proliferating cells or stem cells (English)

1 reference

13 August 2017

1

Blagosklonny MV

1 reference

13 August 2017

publication date

1 March 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

20

1 reference

13 August 2017

issue

3

1 reference

13 August 2017

page(s)

385-391

1 reference

Stem cells, cancer, and cancer stem cells

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Cancer stem cells: lessons from leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Cancer, aging and the optimal tissue design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Cancerous stem cells can arise from pediatric brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Concepts of human leukemic development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Therapeutic implications of cancer stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Mechanisms controlling pathogenesis and survival of leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Tissue repair and stem cell renewal in carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Leukaemia stem cells and the evolution of cancer-stem-cell research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Identification of bronchioalveolar stem cells in normal lung and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Regulation of hematopoietic stem cells by the niche.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Molecular evidence for stem cell function of the slow-dividing fraction among human hematopoietic progenitor cells by genome-wide analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Chronic myelogenous leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

The biology of CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Tumour stem cells and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Punish the parent not the progeny.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Nonproliferating CML CD34 progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Breast cancer resistance protein in drug resistance of primitive CD34 38- cells in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

A distinct "side population" of cells with high drug efflux capacity in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2 and ABCG2- cancer cells are similarly tumorigenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Tissue-selective therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Dynamics of chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Detection of BCR-ABL kinase mutations in CD34 cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Retinoid target genes in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Isolation of renal progenitor cells from adult human kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Self-renewal and solid tumor stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

7 January 2021

Noncycling Tumor Cells Are Sensitive Targets for the Antiproliferative Activity of Human Interferon

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

7 January 2021

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

7 January 2021

Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

7 January 2021

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2404075

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404075

1 reference

13 August 2017

1 reference